BIOVAIL/HOECHST-ROUSSEL DILTIAZEM OD APPROVAL EXPECTED
Executive Summary
BIOVAIL/HOECHST-ROUSSEL DILTIAZEM OD APPROVAL EXPECTED "later this year or early 1995," Biovail VP-Scientific Affairs Robert Burford told securities analysts at a Kidder, Peabody generic drugs and drug delivery health care conference in New York City. Toronto-based Biovail filed an NDA for the once-daily formulation of diltiazem for the treatment of hypertension last August.